News

Sanofi-aventis has entered into an exclusive global licensing agreement with the Rockefeller University, New York, for a monoclonal antibody, targeting certain specific forms of the Amyloid Beta parenchymal

The Natural Step and The Dow Chemical has entered into an agreement that is expected to help both organisations to advance their sustainability missions and goals. The agreement,

AstraZeneca and Targacept have entered into a collaboration and license agreement for the global development and commercialisation of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD).

AlphaRx has selected locations in Hong Kong and Shanghai for its corporate headquarters and a new R&D facility respectively. The company said that the initiative will spearhead a

Alkermes and Acceleron Pharma have enetred into a license agreement. Under the terms of the agreement, Alkermes will have worldwide rights to the Medifusion technology in return with

Noxxon Pharma, developing medicines based on its proprietary Spiegelmer technology, has achieved an important milestone in its drug discovery and development partnership with Eli Lilly and Company. Noxxon’s

Santarus has reported that its collaboration partner, Cosmo Technologies (Cosmo), a subsidiary of Cosmo Pharmaceuticals has completed enrollment of 514 patients in the European Phase III clinical trial

Shire has recalled five lots and voluntary market withdrawal of one lot of the attention-deficit/hyperactivity disorder (ADHD) patch Daytrana. Shire is taking this action because some Daytrana patches

Vetter has added new 24,000-square-foot facility at the Illinois Science + Technology Park in Skokie, which is expected to enable life-sciences firms to streamline their early development process